BioMarin Pharmaceutical (NASDAQ: BMRN) Reports Q2 2026 Financial Results After Market Close Thursday August 6 With Total Revenue of $990 Million (+20% Year-Over-Year, Approaching the $1 Billion Quarterly Threshold), Non-GAAP Diluted EPS of $0.54 (Beating the $0.23 Consensus), Continued Commercial Strength From Voxzogo (Vosoritide, C-Type Natriuretic Peptide Analog for Achondroplasia in Children), Contribution From the Completed Amicus Therapeutics Acquisition Including GALAFOLD (Migalastat for Fabry Disease) and POMBILITI + OPFOLDA (Cipaglucosidase Alfa Plus Miglustat for Late-Onset Pompe Disease); ROCTAVIAN (Valoctocogene Roxaparvovec Hemophilia A AAV Gene Therapy) Revenue Continued Declining Following the Q1 2026 Voluntary Market Withdrawal
BioMarin Pharmaceutical (NASDAQ: BMRN) reported Q2 2026 financial results after market close Thursday August 6, 2026 with total revenue of $990 million (+20% year-over-year), approaching the $1 billion quarterly threshold. Non-GAAP diluted EPS of $0.54 beat the $0.23 analyst consensus. Growth drivers: continued commercial strength of Voxzogo (vosoritide, C-type natriuretic peptide analog administered as a daily subcutaneous injection for achondroplasia in pediatric patients); contribution from the completed Amicus Therapeutics acquisition adding GALAFOLD (migalastat for Fabry disease) and POMBILITI + OPFOLDA (cipaglucosidase alfa plus miglustat oral chaperone for late-onset Pompe disease) to the BioMarin rare-disease portfolio; and continued growth of Palynziq (pegvaliase-pqpz for phenylketonuria). ROCTAVIAN (valoctocogene roxaparvovec, hemophilia A AAV gene therapy) revenue continued to decline following the Q1 2026 voluntary market withdrawal announced earlier in the year. The Amicus acquisition adds cost synergies expected to accelerate revenue growth, non-GAAP diluted EPS accretion, non-GAAP operating margin expansion, and operating cash flow through the mid-2030s per BioMarin management commentary. BioMarin's Voxzogo peptide franchise represents one of the sole approved peptide therapies in the pediatric endocrine indication space and continues to demonstrate the commercial scalability of the C-type natriuretic peptide modality.